MedTrace Logo

The Effect of MDZ on Movement During UIA Clipping

NCT05553678 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-10-26

No results posted yet for this study

Summary

This study is a randomized, controlled, double-blinded, and parallel design study. A total 64 patients will be randomized to receive midazolam or normal saline during unruptured intracranial aneurysm clipping surgery.

Conditions

  • Intraoperative Movement

Interventions

DRUG

Midazolam

Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.

DRUG

Normal saline

Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Chang-Hoon Koo · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-29
Primary Completion
2023-09-30
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05553678 on ClinicalTrials.gov